MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.260
-0.050
-2.16%
After Hours: 2.250 -0.01 -0.44% 16:59 12/13 EST
OPEN
2.280
PREV CLOSE
2.310
HIGH
2.390
LOW
2.250
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
4.090
52 WEEK LOW
1.640
MARKET CAP
179.83M
P/E (TTM)
-3.3802
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACRX News

  • Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
  • Zacks.8h ago
  • AcelRx Pharmaceuticals: A More Thorough Review Of Excellent Prospects
  • Seeking Alpha - Article.11/26 07:17
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22 13:18
  • AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
  • Zacks.11/13 14:24

More

Industry

Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.07%

Hot Stocks

Name
Price
%Change

About ACRX

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
More

Webull offers AcelRx Pharmaceuticals Inc (ACRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.